Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193048 | 0.86 | GRM5 (0.33) | GRM5KDR | |
| SCHEMBL3174769 | 0.84 | GCK (0.47) | GPR35CYP3A4CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL3186011 | 0.83 | CYP2A6 (0.36) | GRM5CYP2A6 | |
| SCHEMBL3380124 | 0.83 | CKS1B (0.42) | GPR35GRM5CYP3A4CYP2E1CYP2A6 | |
| SCHEMBL3182625 | 0.83 | TDO2 (0.35) | — | |
| SCHEMBL3186655 | 0.83 | GRM5 (0.47) | GPR35GRM5CYP3A4CYP2E1CYP2A6 | |
| SCHEMBL3183423 | 0.83 | PIK3C3 (0.35) | NPC1RAB9ACYP19A1 | |
| SCHEMBL3175014 | 0.82 | CCNK (0.41) | GPR35GRM5CYP3A4CYP2E1CYP2A6 | |
| SCHEMBL3377500 | 0.82 | GRM5 (0.41) | GPR35GRM5CYP3A4CYP2E1CYP2A6 | |
| SCHEMBL3192916 | 0.82 | PIK3CA (0.33) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | claimed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | claimed |
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | GRM5, GRIK5, GRM1 | GPR35 37/4885GRM5 1/4885CYP3A4 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.